Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monoclonal antibody 96.5
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**monoclonal antibody 96.5** is an experimental monoclonal antibody that was developed for investigational use in oncology, specifically for targeting cancer cell-surface markers. It is a laboratory-generated immunoglobulin designed to bind to a specific antigen, which is most often associated with tumor cells. Its mechanism of action is characteristic of monoclonal antibodies, which may help label cancer cells for immune destruction, block growth signals, or serve as vehicles for cytotoxins or diagnostics. There is scant public information about 96.5 beyond its designation as an investigational monoclonal antibody.
- Other names
- 96.5
Beyond the preview
Go deeper on monoclonal antibody 96.5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monoclonal antibody 96.5.